GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled, Nir; Gillis, Roni; KILIÇKAP, SAADETTİN; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; ÇİÇİN, İRFAN; Basal, Fatma; Yilmaz, Cengiz; Fedor, Moiseenko; KORKMAZ, Taner; Paydas, Semra; Gautschi, Oliver; Zirtiloglu, Alisan; ERALP, YEŞİM; Cinkir, Havva; Sezer, Ahmet; ERMAN, MUSTAFA; Tural, Deniz; TURNA, Zeynep; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David; Ng, Terry; Senler, Filiz; Beypinar, Ismail; Yazilitas, Dogan; Demirkazik, Ahmet; Karaoglu, AZİZ; Okutur, Kerem; Coskun, Hasan; Sendur, Mehmet; Isikdogan, Abdurrahman; ÇABUK, DEVRİM; YUMUK, PERRAN; YILDIZ, İbrahim; Kaplan, M.; ÖZYILKAN, ÖZGÜR; Oztop, İLHAN; Olmez, Omer; Aydin, Kubra; Aydiner, Adnan; Meydan, Nezih; Grinberg, Roxana; Roisman, Laila

doi:10.1016/j.lungcan.2020.07.022

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., ...Daha Fazla

LUNG CANCER, cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 148
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.lungcan.2020.07.022
Dergi Adı: LUNG CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Sayfa Sayıları: ss.48-54
Anahtar Kelimeler: Lorlatinib, Real-world data, ALK, ROS1, CELL LUNG-CANCER, HYBRID CAPTURE, SINGLE-ARM, OPEN-LABEL, CRIZOTINIB, REARRANGEMENT, IMMUNOHISTOCHEMISTRY, MULTICENTER, CRITERIA, RET
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.